iShares Biotechnology ETF
253 hedge funds and large institutions have $2.6B invested in iShares Biotechnology ETF in 2013 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 86 increasing their positions, 76 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
13% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 76
9% more funds holding
Funds holding: 232 → 253 (+21)
Holders
253
Holding in Top 10
12
Calls
$184M
Puts
$147M
Top Buyers
| 1 | +$62.9M | |
| 2 | +$30.2M | |
| 3 | +$26.4M | |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$17.6M |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$10.4M |
Top Sellers
| 1 | -$98.6M | |
| 2 | -$69.3M | |
| 3 | -$56.8M | |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$35.1M |
| 5 |
JPMorgan Chase & Co
New York
|
-$16.9M |